Bottle and glass: Cephalon recalls Treanda after glass fragments found in vial
This article was originally published in Scrip
Teva's Cephalon has voluntarily recalled one lot of its injectable leukaemia drug Treanda (bendamustine HCL), after glass fragments were found in one of the vials. The affected lot was distributed between March and October 2011, and Teva does not believe that much of the lot remains in stock. The FDA has warned that potential safety issues include disruption of blood flow resulting in tissue/organ damage, though Cephalon has so far received no reports of adverse events. Patients have been advised to return the product and cease using it, and wholesalers, distributors, hospitals and providers have been notified.